Tremelimumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France) and HIRA (South Korea) recommended or restricted tremelimumab, while AOTMIT (Poland) did not recommend it.
The record spans 2.5 years, opening at HAS (France) on 24 May 2023 and running to 6 Nov 2025.
CIPM (Spain) changed its position: not recommended on 29 Jan 2024, recommended by 20 Mar 2024, after a resubmission.
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — PBAC (Australia), SMC (Scotland) and PHARMAC (New Zealand) among them — hold no record for tremelimumab at all.
The file is active: 9 of 9 records date from 2023 or later.
Against its own class, tremelimumab is an outlier: 50% of its decisive outcomes were positive, where molecules sharing ATC class L01F average 73%.
HAS (France) was first to assess tremelimumab, on 24 May 2023; HIRA (South Korea) did not open a file until 4 Sep 2025 — a moderate spread of 2.3 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 3 years in total.
4 of the 5 agencies here assessed tremelimumab more than once, HIRA (South Korea) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed tremelimumab.
The full ledger for tremelimumab reads 3 recommended, 3 not recommended, 2 no benefit and 1 deferred.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 17 Sep 2025 | programu lekowego B.5. Leczenie chorych na raka wątrobowokomórkowego (ICD-10: C22.0) lub raka dróg żółciowych (ICD-10: C… | not recommended | source |
| HIRA (South Korea) | 4 Sep 2025 | 진행성 또는 절제 불가능한 간세포암 성인 환자의 1 차 치료로서 더발루맙과의 병용 요법 | deferred for re-review | source |
| CIPM (Spain) | 20 Mar 2024 | Indicacio nes terapéutica s autorizada s: IMJUDO en combinación con durvalumab está indicado para el tratamiento de prim… | financed by the SNS · art. 92 a, c | source |
| G-BA (Germany) | 5 Oct 2023 | Imjudo — benefit assessment §35a | added benefit: not proven | source |
| HAS (France) | 24 May 2023 | Listing (Transparency Committee) | SMR substantial · ASMR IV | source |
4 further decisions for tremelimumab, across 4 agencies, are not shown here. They include the most recent record on file, 6 Nov 2025 from HIRA (South Korea); its outcome is in the subscriber dataset. They link to 4 further source documents.
Related molecules
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
- rituximab — same ATC class L01F — Antineoplastics
- bevacizumab — same ATC class L01F — Antineoplastics
- blinatumomab — same ATC class L01F — Antineoplastics
Coverage: 9 decisions for tremelimumab from 5 agencies, 2023 to 2025. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.